NDA 207795 · Bausch and Lomb
Vyzulta
Latanoprostene Bunod · Ophthalmic
NovelLast checked: Nov 20, 2026Latest source record: Jun 11, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Nov 2, 2017
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Latanoprostene Bunod" as an intervention, any sponsor and status, largest first.
- Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01749904 · 420 participants · Start Jan 31, 2013 · Primary completion Jun 2, 2015
Drug: BOL-303259-X; Timolol and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
Sites: Rochester, New York
- Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01749930 · 420 participants · Start Jan 2013 · Primary completion May 2015
Drug: BOL-303259-X; Timolol and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
Sites: Rochester, New York
- Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01223378 · 413 participants · Start Dec 13, 2010 · Primary completion Dec 20, 2011
Drug: BOL-303259-X; Latanoprost · For: Intraocular Pressure
Sites: Rochester, New York
- Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHTPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01895972 · 130 participants · Start Jul 5, 2013 · Primary completion Apr 2, 2015
Drug: Latanoprostene bunod · For: Glaucoma; Ocular Hypertension
Sites: Bridgewater, New Jersey
University of California, San DiegoAcademic, hospital or other
NCT03931317 · 70 participants · Start Dec 3, 2018 · Primary completion May 20, 2021
Drug: Latanoprostene bunod 0.024% QD; Timolol maleate 0.5% BID · For: OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension
Sites: La Jolla, California
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT03949244 · 47 participants · Start Aug 15, 2019 · Primary completion Oct 1, 2020
Drug: Latanoprost 0.005%; Latanoprost bunod 0.024% and 1 more · For: Glaucoma, Open-Angle
Sites: New York, New York
Bausch & Lomb IncorporatedIndustry
NCT01707381 · 25 participants · Start Nov 2012 · Primary completion Dec 2013
Drug: BOL-303259-X; Timolol maleate · For: Ocular Hypertension; Open Angle Glaucoma
Sites: La Jolla, California
Bausch & Lomb IncorporatedIndustry
NCT01895985 · 24 participants · Start Jul 2013 · Primary completion Aug 2013
Drug: Latanoprostene bunod · For: Intraocular Pressure
Sites: Madison, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vyzulta (Latanoprostene Bunod)
2024 spending
$128M
Beneficiaries
75,825
292,207 claims
Per beneficiary
$1,692
$98.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $37,642,503 |
| 2021 | $57,633,322 |
| 2022 | $86,520,403 |
| 2023 | $117,369,728 |
| 2024 | $128,286,738 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial.
El-Nimri NW, Moghimi S, Penteado RC, et al. · Am J Ophthalmol 2022 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Harasymowycz P, Royer C, Cui AX, et al. · Br J Ophthalmol 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
Weinreb RN, Liebmann JM, Martin KR, et al. · J Glaucoma 2018 · Clinical Trial, Phase III, Comparative Study
- Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
Medeiros FA, Martin KR, Peace J, et al. · Am J Ophthalmol 2016 · Multicenter Study, Randomized Controlled Trial
- A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
Weinreb RN, Ong T, Scassellati Sforzolini B, et al. · Br J Ophthalmol 2015 · Clinical Trial, Phase II, Comparative Study
- Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Kawase K, Vittitow JL, Weinreb RN, et al. · Adv Ther 2016 · Clinical Trial, Multicenter Study
Sponsor: Bausch and Lomb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.